TLSA
Tiziana Life Sciences Ltd
1.10$
-4.5%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +276.0% | -45.4% | -63.7% | +277.3% | -73.8% | +3,808.0% | -30.9% | -45.8% | -54.0% | -7.4% | +1.9% | |
| – | +276.0% | -45.7% | -63.9% | +280.6% | -83.4% | +6,034.3% | -30.6% | -50.1% | -69.8% | +2.3% | +13.9% | |
| – | +292.9% | -47.2% | -99.0% | +10,930.9% | -97.1% | +42,922.2% | -35.9% | -57.0% | -93.5% | +214.8% | +7.7% | |
| – | +292.9% | -47.2% | -99.0% | +10,930.9% | -97.1% | +42,922.2% | -35.9% | -57.0% | -93.5% | +214.8% | +7.7% | |
| – | +172.3% | -65.6% | +1,556.0% | -16.6% | -0.6% | +194.5% | +39.3% | +11.2% | +3.3% | -39.0% | +15.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -13.1% | -71.2% | +6,171.4% | -18.0% | -95.3% | +2,188.2% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | -2.0% | – | – | – | – | |
| – | +9.2% | +132.8% | +102.3% | +81.8% | -6.3% | +38.1% | -8.8% | -8.5% | -3.7% | +10.5% | +55.7% | |
| – | +9.2% | +132.8% | +102.3% | +91.9% | -17.3% | +43.1% | -5.4% | -11.7% | -1.9% | +12.4% | +52.5% | |
| – | +4.9% | +4.2% | +4.0% | +32.2% | +183.8% | +162.7% | -41.3% | -91.0% | +13.1% | -23.2% | +109.4% | |
| – | +391.2% | +286.3% | +128.3% | +38.7% | +5.6% | -17.0% | +30.9% | +12.6% | -16.6% | +34.9% | +28.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +378.6% | -61.0% | -150.8% | – | -906.8% | – | -9.7% | -52.6% | -71.7% | -28.9% | -98.7% | |
| – | – | – | -369.6% | – | – | – | – | – | – | – | – | |
| – | +718.6% | +13.7% | +9.9% | +16.7% | +0.0% | -28.7% | +0.6% | +3.7% | +0.0% | +5.1% | +10.9% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.